{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:40:14Z","timestamp":1778334014813,"version":"3.51.4"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,4,1]]},"DOI":"10.5551\/jat.63382","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T22:12:58Z","timestamp":1655935978000},"page":"326-334","source":"Crossref","is-referenced-by-count":20,"title":["A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL\/6 Mice"],"prefix":"10.5551","volume":"30","author":[{"given":"Uugantsetseg","family":"Munkhjargal","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"},{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byambasuren","family":"Ganbaatar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Suto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ise","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kusunose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Soeki","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuzo","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB and Tsao CW. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation, 2020; 141: e139-e596","DOI":"10.1161\/CIR.0000000000000757"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Fuller PJ and Young MJ. Mechanisms of mineralocorticoid action. Hypertension, 2005; 46: 1227-1235","DOI":"10.1161\/01.HYP.0000193502.77417.17"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pascual-Le Tallec L and Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol, 2005; 19: 2211-2221","DOI":"10.1210\/me.2005-0089"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999; 341: 709-717","DOI":"10.1056\/NEJM199909023411001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ and Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21","DOI":"10.1056\/NEJMoa1009492"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003; 348: 1309-1321","DOI":"10.1056\/NEJMoa030207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Nguyen Dinh Cat A and Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens, 2012; 21: 147-156","DOI":"10.1097\/MNH.0b013e32834fb25b"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF and Phillips LS. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc, 2019; 8: e011295","DOI":"10.1161\/JAHA.118.011295"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S, Blankstein R and Di Carli MF. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation, 2012; 126: 1858-1868","DOI":"10.1161\/CIRCULATIONAHA.112.120402"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bender SB, McGraw AP, Jaffe IZ and Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes, 2013; 62: 313-319","DOI":"10.2337\/db12-0905"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Bruder-Nascimento T, da Silva MA and Tostes RC. The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr, 2014; 6: 90","DOI":"10.1186\/1758-5996-6-90"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Adel H, Taye A and Khalifa MM. Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol, 2014; 387: 1187-1197","DOI":"10.1007\/s00210-014-1048-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Brown SM, Meuth AI, Davis JW, Rector RS and Bender SB. Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature. Pharmacol Res, 2018; 134: 100-108","DOI":"10.1016\/j.phrs.2018.06.002"},{"key":"14","unstructured":"14) Schafer A, Vogt C, Fraccarollo D, Widder J, Flierl U, Hildemann SK, Ertl G and Bauersachs J. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol, 2010; 61: 45-52"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Silva MA, Bruder-Nascimento T, Cau SB, Lopes RA, Mestriner FL, Fais RS, Touyz RM and Tostes RC. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO\/GC signaling. Front Physiol, 2015; 6: 269","DOI":"10.3389\/fphys.2015.00269"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hashikabe Y, Suzuki K, Jojima T, Uchida K and Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol, 2006; 47: 609-613","DOI":"10.1097\/01.fjc.0000211738.63207.c3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kirsch T, Beese M, Wyss K, Klinge U, Haller H, Haubitz M and Fiebeler A. Aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity by rearrangement of the actin cytoskeleton. Hypertension, 2013; 61: 501-558","DOI":"10.1161\/HYPERTENSIONAHA.111.196832"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y and Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension, 2006; 48: 165-171","DOI":"10.1161\/01.HYP.0000226054.53527.bb"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sanz-Rosa D, Oubi\u00f1a MP, Cediel E, De las Heras N, Aragoncillo P, Balfag\u00f3n G, Cachofeiro V and Lahera V. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal, 2005; 7: 1294-1301","DOI":"10.1089\/ars.2005.7.1294"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Thai HM, Do BQ, Tran TD, Gaballa MA and Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail, 2006; 12: 240-245","DOI":"10.1016\/j.cardfail.2006.01.002"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Toda N, Nakanishi S and Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol, 2013; 168: 519-533","DOI":"10.1111\/j.1476-5381.2012.02194.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G and Gaudio C. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol, 2015; 200: 25-29","DOI":"10.1016\/j.ijcard.2015.05.127"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M and Sada T. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol, 2015; 761: 226-234","DOI":"10.1016\/j.ejphar.2015.06.015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Arai K, Tsuruoka H and Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol, 2015; 769: 266-273","DOI":"10.1016\/j.ejphar.2015.11.028"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F and Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol, 2018; 84: 1821-1829","DOI":"10.1111\/bcp.13616"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Ito S, Itoh H, Rakugi H, Okuda Y and Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens, 2019; 33: 542-551","DOI":"10.1038\/s41371-019-0207-x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M and Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension, 2020; 75: 51-58","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Takahashi M, Ubukata O, Homma T, Asoh Y, Honzumi M, Hayashi N, Saito K, Tsuruoka H, Aoki K and Hanzawa H. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Lett, 2020; 594: 1615-1623","DOI":"10.1002\/1873-3468.13746"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pham PT, Fukuda D, Yagi S, Kusunose K, Yamada H, Soeki T, Shimabukuro M and Sata M. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. Sci Rep, 2019; 9: 11206","DOI":"10.1038\/s41598-019-47474-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Matsumoto S, Shimabukuro M, Fukuda D, Soeki T, Yamakawa K, Masuzaki H and Sata M. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)\/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol, 2014; 13: 30","DOI":"10.1186\/1475-2840-13-30"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Suto K, Fukuda D, Shinohara M, Ganbaatar B, Yagi S, Kusunose K, Yamada H, Soeki T, Hirata KI and Sata M. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor alpha Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice. J Atheroscler Thromb, 2021; 28: 1349-1360","DOI":"10.5551\/jat.61101"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, Thum T, Bauersachs J, Ertl G, Zou MH, F\u00f6rstermann U and M\u00fcnzel T. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis, 2008; 198: 65-76","DOI":"10.1016\/j.atherosclerosis.2007.10.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Chen B, Zhao Q, Ni R, Tang F, Shan L, Cepinskas I, Cepinskas G, Wang W, Schiller PW and Peng T. Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes. Cardiovasc Diabetol, 2014; 13: 88","DOI":"10.1186\/1475-2840-13-88"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Knapp M, Tu X and Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin, 2019; 40: 1-8","DOI":"10.1038\/s41401-018-0042-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Sch\u00e4fer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, L\u00fcscher TF, Verrey F and Matter CM. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J, 2013; 34: 3515-3524","DOI":"10.1093\/eurheartj\/eht095"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Raz-Pasteur A, Gamliel-Lazarovich A, Coleman R and Keidar S. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 2012; 60: 508-512","DOI":"10.1097\/FJC.0b013e31826f5535"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H and Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension, 2005; 46: 1135-1139","DOI":"10.1161\/01.HYP.0000184640.81730.22"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kobayashi N, Fukushima H, Takeshima H, Koguchi W, Mamada Y, Hirata H, Machida Y, Suzuki N, Yokotsuka F, Tabei K, Kobayashi E, Fukuda N and Ishimitsu T. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens, 2010; 23: 1007-1013","DOI":"10.1038\/ajh.2010.91"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Maron BA, Zhang YY, Handy DE, Beuve A, Tang SS, Loscalzo J and Leopold JA. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem, 2009; 284: 7665-7672","DOI":"10.1074\/jbc.M809460200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH and Schmieder RE. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension, 2003; 42: 156-160","DOI":"10.1161\/01.HYP.0000083298.23119.16"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W and Brunner-La Rocca HP. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension, 2007; 50: 82-88","DOI":"10.1161\/HYPERTENSIONAHA.107.088955"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R and Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation, 2003; 108: 2400-2406","DOI":"10.1161\/01.CIR.0000093188.53554.44"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Farquharson CA and Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond), 2002; 103: 425-431","DOI":"10.1042\/cs1030425"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Farquharson CA and Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation, 2000; 101: 594-597","DOI":"10.1161\/01.CIR.101.6.594"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Tsuchiya K, Yoshimoto T and Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J, 2009; 56: 553-559","DOI":"10.1507\/endocrj.K09E-014"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Malinski T, Taha Z, Grunfeld S, Patton S, Kapturczak M and Tomboulian P. Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. Biochem Biophys Res Commun, 1993; 193: 1076-1082","DOI":"10.1006\/bbrc.1993.1735"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Li L, Guan Y, Kobori H, Morishita A, Kobara H, Masaki T, Nakano D and Nishiyama A. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res, 2019; 42: 769-778","DOI":"10.1038\/s41440-018-0187-1"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Arai K, Morikawa Y, Ubukata N and Sugimoto K. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res, 2020; 43: 1204-1213","DOI":"10.1038\/s41440-020-0495-0"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V and Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology, 2006; 147: 5363-5373","DOI":"10.1210\/en.2006-0944"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/4\/30_63382\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:49:40Z","timestamp":1715316580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/4\/30_63382\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63382","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"article-number":"63382"}}